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Highlights 
 
• The majority of cases were in the age group of 50 to 60 years of old. 
 
•A total of 2964 cases of COVID-19 were investigated. 
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•The male-to-female ratio was 1.93:1. 
 
• A significant effect of age, gender and comorbidities on the mortality.  
 
•The Case Fatality Rate among understudy cases was 8.06%. 
 
1. Background 
For the first time in late December 2019, cases of pneumonia with an unknown cause were reported 
in Wuhan, China, and later in January 2020, a new type of coronavirus was identified as the cause 
of those pneumonia cases [1]. The World Health Organization (WHO) chose the official name of 
COVID- 19 (stand for coronavirus disease 2019), for the disease, as well as the term SARS-COV-
2(severe acute respiratory syndrome coronavirus 2) for the virus[2]. A similar to SARS and Middle 
East Respiratory Syndrome (MERS) coronaviruses trend has been seen in the epidemiology of this 
emerging disease[3]. In March 11, 2020, the WHO announced COVID-19 as a pandemic[4].  The 
disease is highly contagious and each infected person could infect at least 3 other people on 
average[5]. As of, April 15, 2020, 76389 patients with COVID- 19 have been identified in Iran, of 
which 4777 deaths have been occurred by the virus. According to statistics, Iran ranks sixth after 
the United States , Italy, Spain, , France and the United Kingdom in the number of deaths due to 
COVID- 19   [6]. The first deaths from COVID-19 reported officially on Feb 19, 2020[7]. 
Identifying the epidemiological characteristics of this disease will help to make appropriate 
decisions and thus control the epidemic. Certain epidemiological features of COVID-19 have been 
previously reported [8-11]. However, these studies were based on relatively small sample sizes, 
and mostly from China. The aim of this study was characterization of the epidemiological features 
of COVID-19 in Iran as a country with a population of more than 83 million people [12]in the 
Middle East and the Persian Gulf region. Here, we report the results of an epidemiological analysis 
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of all cases hospitalized in Baqiyatallah Hospital, affiliated to Baqiyatallah University of Medical 
Sciences (BMSU), in Tehran ,Iran.  
 
2. Method  
2.1. Study design and data collection 
The present study was a retrospective, epidemiological study that has been performed on 
hospitalized cases of COVID-19 in Baqiyatallah hospital in Tehran. According to hospital data, 
patients were admitted from 19 February 2020, to 15 April   2020. All patient information is kept 
confidential.  Patients were confirmed by RT-PCR (Reverse transcription-polymerase chain 
reaction) using throat and nose swab specimens from the upper respiratory tract or clinically 
diagnosed based on lung imaging features specially Chest CT(Computed tomography) scan ground 
glass pathognomonic features consistent with coronavirus pneumonia, depending on the 
physician's orders.  All registered cases at the hospital had a national unique code, so there were 
no duplicates. The study variables were as follows: gender, age, final outcome (including death or 
survival), type of comorbidities.   
2.2. Statistical Analysis 
Descriptive analyses of the variables were expressed as mean (±Standard Deviation=SD), median 
(with an interquartile range =IQR=Q1-Q3), or number (%). The analyses were based on non-
missing data, and missing data were not imputed. The age and sex distribution were examined and 
relevant charts were drawn. Sex ratio (male to female) and the case fatality rate (CFR) were 
calculated. To investigate the effect of age, gender, and comorbidities on mortality, a multiple 
logistic regression model was used. Adjusted Odds Ratio (OR) with 95% Confidence Interval (CI) 
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was calculated. The α: 0.05 was considered as a significance level. The data were analyzed using 
the STATA version 11.0 and Excel version 2010. 
 
3. Results 
From February 19, 2020 to April 15, 2020, a total of 12870 patients referred to the hospital 
emergency department, of which 2968 were hospitalized with COVID-19 diagnosis. The mean of 
age was 55.50 ±15.15 years and the median of age was 56(46-65) years. The majority of cases 
were in the age group of 50 to 60 years (Fig 1). Also, most cases (66%) were male. The male-to-
female ratio was 1.93:1. CFRs are shown in Table 1.  Totally 239 deaths occurred during the entire 
study period, so the overall CFR was calculated to be 1.85% based on the total number of patients 
(both outpatient and inpatient) and also CFR was calculated to be 8.06% among hospitalized 
patients.   
Among the 239 deaths, the mean of age was 65.38 ±13.67 years and the median of age was 65(57-
75) years. A majority (160 = 66.94%) were ≥60 years of age and 38(15.89%) had comorbidities. 
Patients over 80 years of age had the highest CFR among the age groups (19.27%). The CFR was 
8.54% and 7.13% for men and women, respectively. A total of 323(10.89%) of patients had chronic 
underlying diseases. As  shown in Fig 2, Diabetes, chronic respiratory diseases, hypertension, 
cardiovascular diseases, chronic kidney diseases and cancer were the most common comorbidities 
with 3.81, 2.02 , 1.99 , 1.25, 0.60 and 0.57 %, respectively. While patients who reported no 
comorbidity had a CFR of 7.61%,  patients with comorbid conditions had higher rates (9.73% for 
diabetes, 10.81% for those with cardiovascular disease, 15% for those with chronic respiratory 
disease, and 13.55% for those with hypertension, 16.66% for chronic Kidney diseases and 5.88% 
for patients with cancer. Fig3 indicates the number of cases as well as deaths based on the date of 
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admission from February 19, 2020 to April 15, 2020.  The results of logistic regression showed 
that male gender significantly increased odds of death by 45 % (OR=1.45, 95% CI: 1.08-1.96). 
Also, for a one-year increase in the age, the odds of death increases by 5% (OR=1.05, 95% CI: 
1.04-1.06). Having underlying disease also increases the odds of mortality by 53% (OR=1.53, 95% 
CI: 1.04-2.24) this was also statistically significant (Table 2). 
4. Discussion 
The present epidemiological study on 2964 COVID-19 hospitalized cases between 19 February 
2020 to 15 April  2020 , provides information about the disease and the outbreak in Iran.   As 
shown in Figure 1, the increasing trend of hospitalized cases over a short period of time (19 
February to March 11) is clear. This finding could confirm the rapid spread of the disease in the 
population. The peak of hospitalization occurred on March 11, and since March 17, the number of 
hospitalized cases has decreased slightly. The data appear to indicate a propagated source pattern 
of spread. Estimates suggest that around 14% of people  infected with COVID-19 have severe 
disease, and 6% are critically ill  [13], hence, about 20% of all cases of the disease are usually need 
to be hospitalized. Since Baqiyatallah Hospital is a referral center in Tehran, so, it can be concluded 
that there is probably a similar trend in the general population. Among the 239 deaths, a majority 
(160 = 66.94%) has been ≥60 years of age and 38(15.89%) had comorbidities such as diabetes, 
hypertension and chronic respiratory diseases and etc. According to the results of our study, overall 
CFR was calculated to be 1.85% based on the total number of patients (both outpatient and 
inpatient). Other studies have been reported CFR ranged from 2.5% to 3%,[14, 15]. CFR was also 
calculated to be 8.06% among hospitalized patients, it is not surprising that the CFR among 
hospitalized patients was high as patients with a better general condition who were not hospitalized 
and therefore not included in the denominator. A  recently published systematic review and meta-
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analysis reports a CFR of over 13% in 7 studies describing 632 hospitalized patients[16]. Also, 
two studies from China, reported a CFR of 15% [8]and 11% [9], respectively. Besides, in a study 
the CFR  has been reported to be as high as 49% among critical hospitalized cases[17]. The results 
of logistic regression showed the significant effects of age , male gender and underlying diseases 
on risk of death in patients with COVID-19.  In line with other studies[18, 19] the regression 
analysis in our study revealed that older age is associated with higher risk of mortality. Some 
studies showed that older age is associated with declined immune system ability[20]. Previously, 
older age has been reported as an associated factor for  mortality in SARS [21] and MERS[22]. 
The present study showed that male gender significantly increases mortality (OR=1.45, 95% CI: 
1.08-1.96). We also observed a greater number of males than females in the 2964 cases of COVID-
19 infection. MERS-CoV and SARS-CoV have also been found to infect more men than 
women[23, 24]. This finding is consistent to other studies [9, 25]. The less susceptibility to 
infection among women could be attributed to the X chromosome and sex hormones, which have 
been reported to play role in innate and adaptive immunity[26].  Furthermore, according to our 
results, 10.89% of patients had chronic underlying diseases, mainly diabetes, chronic respiratory 
diseases , hypertension and cardiovascular diseases; this is similar to MERS-CoV [24]. In line with 
other studies[27-29] , our result also showed that, having comorbidities had a statistically 
significant effect on Mortality (OR=1.53, 95% CI: 1.04-2.24). A study suggested that compared 
to patients with no comorbidities, the risk of death in patients with influenza is more than in those 
who had cardiovascular disease and hypertension[30]. As far as our knowledge shows, the present 
study is the first descriptive study of the COVID-19 outbreak in Iran, with a large sample size. 
Although the sample size in the present study is a major advantage, unfortunately, more detailed 
patient information, particularly regarding clinical outcomes and early symptoms was unavailable 
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at the time of analysis. Importantly, this may limit the conclusions from this data. However, the 
data in this study permit an early assessment of the epidemiological characteristics of COVID-19 
cases in Tehran, Iran. Further studies in outpatient, primary care, or community settings would 
help to get a full picture of the clinical presentation, natural history, risk factors and the spectrum 
of clinical severity of the disease. In addition, further efforts should be made to compensate for the 
above mentioned limitation in future studies.  Rapid, reliable and feasible diagnostic tests are 
important, as well as differential diagnoses based on clinical descriptions by physicians. Careful 
national surveillance is essential to monitor the disease and its epidemiological characteristics 
including infectivity, host adaption, viral evolution, transmissibility, and pathogenicity. Efforts 
and initiatives at the national, regional and global levels need to be made to cut off the disease 
transmission chain.  
5. Conclusion 
The results of this study emphasize the significant effect of older age , male gender and underling 
diseases on the risk of mortality among COVID-19 patients, which has been mentioned previously 
in other studies. So it is recommended to take preventative measures more seriously in the elderly 
patients. Also regarding medical care, it is important to pay special attention to elderly patients 
who also have underlying diseases. As COVID-19 is considered a global health threat, it still needs 
to be investigated deeply.  
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 Fig1. The distribution of all cases and deaths in each age group (n=2964) 
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Fig2. The distribution of comorbidities among all Covid-19 cases as well as cases that have died. 
 
Fig3. The distribution of Covid-19 patients according to date of Hospital  admission (n=2964). 
 
Table1. Demographics and characteristics of patients infected with COVID-19 
 
 
 
* Other diseases: Liver disorders, chronic rheumatic diseases, Anemia, Immunodeficiency disorders. 
†Recovery refers to patients who have recovered and been discharged. Hospitalized patients are patients who are 
still hospitalized and under care. 
 
Table 2- The effective epidemiological factors on Mortality of Covid-19 Patients 
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Variable 
 
Subgroups 
 
All Cases 
 N (%) 
 
Deaths,  
N 
 
Case 
Fatality Rate 
(%) 
 
Overall 
- 2964  
239 
 
8.06 
 
 
 
 
 
Age, years 
0–10 2(0.07) 0 - 
10–20 8(0.27) 0 - 
20–30  
97(3.27) 
 
1 1.03 
30–40 416(14.03) 11 2.64 
40–50 452(15.25) 13 2.87 
50–60 825(27.83) 54 6.54 
60–70 622(20.98) 71 11.41 
70–80 350 (11.80) 52 14.85 
≥80 192(6.50) 37 19.27 
Gender Female 1009(34.00) 72 7.13 
Male 825(66.00) 167 8.54 
 
 
Comorbidity 
No 2641(89.10) 201 7.61 
Diabetes 113(3.81) 11 9.73 
Chronic respiratory disea
se 
60(2.02) 9 15 
Hypertension 59(1.99) 8 13.55 
Cardiovascular disease 37(1.25) 4 10.81 
Chronic Kidney disease 18(0.60) 3 16.66 
Cancer (any) 17(0.57) 1 5.88 
Other diseases* 19(0.64) 2 10.52 
Patient Current 
Status† 
 
 
 
 
 
Recovery 2639(89.03) - - 
Hospitalized 86(2.90) - - 
 
Death 239(8.06) - - 
Variable Odds Ratio Standard 
Error 
P-Value [95% Confidence Interval] 
Comorbidity  1.53 0.19 0.03 1.04 - 2.24 
Age 1.05 0.005 <0.0001 1.04 - 1.06 
Male Gender 1.45 0.15 0.01 1.08 - 1.96 
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